María Martín López

Clinical research scientist with a broad background in advanced therapies, including cell therapy and tissue engineering, making me adaptable to any therapeutic area with both, preclinical and clinical expertise. Experienced and skilled in design, execution, result analysis, interpretation and reporting studies.

• Extensive knowledge in drug development process, good manufacturing practices (GMP) and human pathophysiology & diseases (e.g., spinal cord injury, stroke and vascular diseases).
• Experienced in clinical study protocol development and execution.
• Expert in analyzing scientific data including interpretation and summarizing for publications (10 publications in JCR indexed peer reviewed scientific journals).
  

• Martín-López, M., Rosell-Valle, C., Arribas-Arribas, B. et al., “Bioengineered tissue and cell therapy products are efficiently cryopreserved with pathogen-inactivated human platelet lysate-based solutions”, Stem Cell Res Ther 14, 69 (2023). https://doi.org/10.1186/s13287-023-03300-z.
• E. Gomez-Gonzalez et al.,”Polarimetric imaging for the detection of synthetic models of SARS-CoV-2: A proof of concept”, Journal of Quantitative Spectroscopy and Radiative Transfer, vol. 302, March 2023, doi: 10.1016/j.jqsrt.2023.108567.
• García-Delgado, A. B., Campos-Cuerva, R., Rosell-Valle, C., Martin-López, M ., Casado, C., Ferrari, D., Márquez-Rivas, J., Sánchez-Pernaute, R., & Fernández-Muñoz, B. (2022). Brain Organoids to Evaluate Cellular Therapies. Animals, 12(22), 3150. https://doi.org/10.3390/ani12223150
• C. Rosell-Valle and M. Martin-Lopez et al., “Inactivation of human plasma alters the structure and biomechanical properties of engineered tissues,” Front. Bioeng. Biotechnol., vol. 10, Aug. 2022, doi: 10.3389/fbioe.2022.908250.
• E. Gomez-Gonzalez et al., “Optical imaging spectroscopy for rapid, primary screening of SARS-CoV-2: a proof of concept,” Sci. Rep., vol. 12, no. 1, p. 2356, Dec. 2022, doi: 10.1038/s41598-022-06393-3.
• M. B. González et al., “Optimization of human platelet lysate production and pathogen reduction in a public blood transfusion center,” Transfusion, vol. 62, no. 9, pp. 1839–1849, Sep. 2022, doi: 10.1111/trf.17045.
• E. Gomez-Gonzalez et al., “Hyperspectral image processing for the identification and quantification of lentiviral particles in fluid samples,” Sci. Rep., vol. 11, no. 1, p. 16201, Dec. 2021, doi: 10.1038/s41598-021-95756-3.
• M. Martín-López , E. González-Muñoz, E. Gómez-González, R. Sánchez-Pernaute, J. Márquez-Rivas, and B. Fernández-Muñoz, “Modeling chronic cervical spinal cord injury in aged rats for cell therapy studies,” J. Clin. Neurosci., vol. 94, pp. 76–85, Dec. 2021, doi: 10.1016/j.jocn.2021.09.042.
• M. Martin-Lopez , B. Fernandez-Muñoz, and S. Canovas, “Pluripotent Stem Cells for Spinal Cord Injury Repair,” Cells, vol. 10, no. 12, p. 3334, Nov. 2021, doi: 10.3390/cells10123334.
• B. Fernández-Muñoz et al., “Retrieval of germinal zone neural stem cells from the cerebrospinal fluid of premature infants with intraventricular hemorrhage,” Stem Cells Transl. Med., vol. 9, no. 9, pp. 1085–1101, Sep. 2020, doi: 10.1002/sctm.19-0323.

Spanish native and English (C1)

Advanced therapies, cell therapy, clinical development, clinical study, clinical trials, drug development, English, experiments, GMP, interpretation, international experience, protocols, research, SOP, tissue engineering, validation.